Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms

Br J Haematol. 2023 Jul;202(2):308-317. doi: 10.1111/bjh.18834. Epub 2023 May 4.

Abstract

Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony forming progenitor assays derived from single cells to study mutation acquisition. Further, the hierarchy of mutations within distinct cell lineages was evaluated. NGS revealed mutations in three epigenetic modulator genes (TET2, DNMT3A, ASXL1) as most common co-mutations to the classical driver mutations. JAK2V617F as well as DNMT3A and TET2 mutations were detected as primary events in disease formation and most cases presented with a linear mutation pattern. Mutations appear mostly in the myeloid lineages but can also appear in lymphoid subpopulations. In one case with a double mutant MPL gene, mutations exclusively appeared in the monocyte lineage. Overall, this study confirms the mutational heterogeneity of classical MPNs and highlights the role of JAK2V617F and epigenetic modifier genes as early events in hematologic disease formation.

Keywords: DNMT3A; JAK2; MPN; TET2; clonal evolution; clonal hierarchy; single cells.

MeSH terms

  • Calreticulin / genetics
  • Clonal Evolution / genetics
  • Humans
  • Janus Kinase 2 / genetics
  • Janus Kinase 2 / metabolism
  • Mutation
  • Myeloproliferative Disorders* / genetics
  • Myeloproliferative Disorders* / pathology
  • Neoplasms*
  • Phenotype

Substances

  • Janus Kinase 2
  • Calreticulin